Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $16.3 million.

  • Artiva Biotherapeutics' Cash from Investing Activities rose 11246.13% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.4 million, marking a year-over-year increase of 13798.55%. This contributed to the annual value of -$120.5 million for FY2024, which is 36376.52% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Cash from Investing Activities stood at $16.3 million for Q3 2025, which was up 11246.13% from $21.1 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Cash from Investing Activities high stood at $21.1 million for Q2 2025, and its period low was -$130.6 million during Q3 2024.
  • For the 3-year period, Artiva Biotherapeutics' Cash from Investing Activities averaged around -$8.5 million, with its median value being $1.3 million (2024).
  • In the last 5 years, Artiva Biotherapeutics' Cash from Investing Activities tumbled by 2639655.17% in 2024 and then soared by 146575.24% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Cash from Investing Activities stood at -$2.7 million in 2023, then soared by 63.79% to -$966000.0 in 2024, then skyrocketed by 1785.09% to $16.3 million in 2025.
  • Its Cash from Investing Activities stands at $16.3 million for Q3 2025, versus $21.1 million for Q2 2025 and $10.0 million for Q1 2025.